Bracco molecular imaging subsidiary Blue Earth Diagnostics announced that several abstracts evaluating its PET radiotracer Axumin (fluciclovine F-18) for imaging men with suspected prostate cancer will be presented June 4 at the 2021 American Society of Clinical Oncology (ASCO) virtual annual meeting.
Axumin was approved by the U.S. Food and Drug Administration in 2016 for use in PET imaging to identify the recurrence of prostate cancer based on elevated blood prostate-specific antigen levels following prior treatment.
The abstracts at the ASCO 2021 meeting further evaluate Axumin's efficacy in cancer treatments, the company reported.
